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Abstract
Background: Toxic mercury is still being used today for example by workers mining gold, resulting in diverse
health symptoms in users and individuals in proximity. A considerable burden of disease (BoD) can be assumed,
while previous analyses were limited by data scarcity. Besides limited epidemiological data, neither data about the
health-related quality of life (HRQoL) nor about the disease severity (disability weight, DW) is available. The aim of
the project was to develop disease profiles of chronic metallic mercury vapor intoxication (CMMVI) by including the
HRQoL to improve the data basis for BoD analyses of gold miners exposed to mercury.
Methods: Disease profiles comprising the disease label [a], differentiation into disease stages [b], description of the
cause of exposure [c], a list of common symptoms [d], and an assessment of the HRQoL [e] were developed using
expert elicitation and literature search. The HRQoL was assessed by experts using the five EuroQol dimensions
accompanied by the cognition add-on questionnaire (EQ-5D + C).
Results: The ten sources used for the analyses (interview transcript, presentation, and eight literature reviews)
identified more than 250 terms describing 85 distinguishable health effects of CMMVI. The analysis revealed 29
common symptoms that were frequently mentioned. Moderate and severe CMMVI cases differ regarding their
symptoms and/or symptom severity and HRQoL, resulting in the EQ-5D + C-3L codes 121222 and 233333, respectively.
Conclusions: The profiles should be used to facilitate the ascertainment of CMMVI cases, to compare the HRQoL with
other diseases, to derive DWs for improving BoD estimates, and to foster discussions about how to reduce the
associated burden.
Keywords: Mercury intoxication, Health-related quality of life (HRQoL), EuroQol (EQ-5D + C-3L), Expert elicitation,
Disability weight
Background
The use of mercury in artisanal small-scale gold mining
(ASGM) is a problem of global concern [1] because it
leads to the greatest anthropogenic emission of this toxic
heavy metal worldwide [2, 3]. Mercury is extensively
used in ASGM to extract gold, because amalgamation
does not require high technologies [4]. Mercury binds
the gold of the crushed ore. The resulting amalgam is
smelted so that the mercury vaporizes and the gold
remains [5]. This procedure exposes and endangers not
only the miners and but also residents in close proximity
to enormous quantities of mercury [6].
More than 16 million miners worldwide, especially in
Africa, Asia, and South America, are assumed to use
mercury for gold extraction, while the mercury release is
highest in countries with the lowest technology [4]. Most
of these workers belong to the poorest segments of the
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global society [7] and live outside the regulating systems
with respect to prevention, reporting, and compensation
of occupational diseases [8]. As a consequence, their
diseases often are undetected and -reported and the
associated burden is ignored or not recognized [8]. A
considerable burden of disease (BoD) can be assumed,
although previous BoD analyses were limited by data
scarcity [9–13].
The BoD concept allows estimating and comparing
the health impact of (risk factor attributable) diseases
expressed as disability-adjusted life years (DALYs) by
combining mortality and morbidity into a single metric
[14–16], while the morbidity is associated with the
health-related quality of life (HRQoL) [17]. The mortal-
ity part of the DALY – expressed as years of life lost due
to premature death (YLL) – is calculated by multiplying
the number of deaths with a standard remaining life
expectancy at the age of death. The morbidity part is
determined by the years lived with disability (YLD) while
prevalence cases (or alternative incident cases multiplied
with duration of the disease) are multiplied with a dis-
ability weight (DW) [15, 18, 19].
The DW is a factor between one, what means a health
state comparable with death, and zero, a health state
without disability [15]. In several studies, panels of experts
or other subgroups were asked to assess the severity of
disease states (e.g., [15, 20–22]). Although more than 200
disease stages were determined in the largest study [22],
specific conditions like the chronic intoxication due to
mercury exposure in ASGM were not considered. A
missing DW is a common limitation when considering
underexplored health effects. For this reason, in previous
studies either provisional DWs were used [9, 11] or the
analyses were not carried out [10]. However, determining
the BoD of health effects with limited data is especially
important to ensure the awareness of policy makers and
to avoid an implicit assumption, that these causes have no
burden [23].
Although there are several ways to derive DWs, they
all heavily rely on descriptions of health states which can
be evaluated by different respondent groups. The descrip-
tions used vary widely, but can generally be divided into
three major sub-groups: disease-specific descriptions,
generic descriptions, and descriptions combining the
aforementioned approaches. Using information about
the HRQoL as generic description and combining it
with disease-specific information has been done previ-
ously [20, 21, 24–28] and is recommended by Haagsma
and colleagues who recently reviewed and compared DW
studies [29].
The aim of the DiWIntox-1 project (first part of
the project ‘disability weights for chronic mercury in-
toxication’) was to develop disease profiles for chronic
intoxications due to mercury in ASGM comprising
disease-specific and generic components by including
information about the HRQoL. The descriptions should
be useful as a starting point to derive DWs for the health
outcome of interest. The paper focusses on the following
research questions: [a] How can the health outcome of
mercury exposed ASGM workers be labelled? [b] In what
way can the health outcome of interest be differentiated in
disease stages? [c] What is the characteristic exposure
situation of ASGM workers using mercury? [d] Which
health symptoms are common for the health outcome of
interest? [e] What is the HRQoL of individuals showing
the health outcome of interest?
Methods
Based on a similar procedure used in previous studies
[20, 21, 30], the following components were included in
the establishment of disease profiles for the DWs: a
disease label [a], classification into disease stages [b], the
exposure setting [c], a list of common symptoms [d],
and an assessment of the HRQoL [e]. For differentiation
into disease stages [b], information on symptom severity
and probability of occurrence (common or uncommon,
degree of severity) were needed. The information about
the exposure [c] and symptoms [d] form the disease-
specific part of the description. The assessment of the
HRQoL [e] belongs to the generic part of the descrip-
tion. The information for the disease profiles (compo-
nents a to e) was obtained by consulting experts and
conducting a systematic literature review. Finally, the
information from the different sources was combined.
Expert elicitation
An expert meeting in Ljubljana, Slovenia, was conducted
in December, 2012. The meeting agenda consisted of oral
presentations and a group interview (Additional file 1; File
S1). One of the presentations (Chronic Hg Intoxication in
the Idrija Mercury Mine; Alfred Kobal) and the interview
were used as data sources for the disease profiles. A
list of references included in the presentation is given
in Additional file 1: File S2.
The methodological design of the interview was based
on a formal expert elicitation protocol developed by
Knol et al. [31] and Slottje et al. [32]. The goal was to
determine and describe all components of the disease
profiles listed above (components [a] to [e]). The inter-
view was recorded and transcribed.
The discussion group was formed by four Slovenian
and one German expert, one interviewer and one stu-
dent assistant (both German). The experts were trained
in medicine, toxicology, or public health, and were expe-
rienced with the effects of mercury on human health
(Additional file 1; File S3). The two medical doctors had
direct experiences with medical examinations of workers
chronically exposed to mercury, either workers from Idrija
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mercury mine in Slovenia, which was closed in 1995, or
with ASGM workers and residents at mining sites in
several countries.
The interview guideline comprised 27 questions; 24
were used to determine the exposure and health out-
come of interest, and three for the evaluation of the
meeting (Additional file 1; File S4). The questions were
designed to guide the discussion in order to meet the
objectives of the project. In addition to the consensus
discussions about disease-specific characteristics, a gen-
eric approach was used to assess the HRQoL applying
the five EuroQol dimensions (mobility, self-care, usual
activities, pain/discomfort, anxiety/depression) plus a
cognition questionnaire (EQ-5D + C) [33–35] (Additional
file 1; File S4; questions 19–24). In the group interview,
questions were answered in an open discussion. Neither
structured instruments (e.g., the Delphi method) nor con-
secutive rounds of written expert opinions were
employed.
The EuroQol group was informed about the EQ-5D + C
application and confirmed its consent. The original proto-
col for EQ-5D questionnaires [34] was adapted, with
experts rather than patients being interviewed (Please
indicate which statement best describes the health state of
a person with the disease). In a consensus discussion, the
participants assessed symptom severity according to the
six dimensions coded in three levels (EQ-5D + C-3L),
defined as 1 for no problems, 2 for problems, and 3 for
severe problems.
Systematic literature review
In addition to the interview, a literature review was
conducted after the meeting to accurately focus on
the health outcome and exposure setting determined
during the interview. The aims were to contribute to
the components [b] and [d]; namely to complete the
list of symptoms and collect information about symptom
severity and the probability of occurrence at different
stages of the disease.
Two approaches ensuring a comprehensive overview
of the published literature by identifying references listed
in PubMed and references not listed in PubMed (see
Fig. 1) were used. First, reports from international institu-
tions with experience in mercury research were obtained
using a snowball system. Reports from the World Health
Organization (WHO) [36–38], the Agency for Toxic
Chronic + Metallic + Mercury 
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Chronic + Metallic + Mercury 
+ Exposure (10 hits)
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Main focus lies on 
selected symptoms
Chronic + Metallic + Mercury 
+ Vapor + Poisoning (3 hits)
Review + Elemental + 
Mercury + Health (26 hits)
a Most references were excluded based on several criteria. b Language: English; Date of publication: January 1999 to March
2013. c PubMed and non-PubMed references used for the DiWIntox project. + Search terms are connected with “AND”.
d Reports from international institutions with experience in mercury research were identified by following a snowball system.
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Fig. 1 Flowchart of the literature search and references used
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Substances and Disease Registry (ATSDR) [39] and the
Encyclopaedia of Occupational Health & Safety from the
International Labour Organization [40] were identified as
important sources to find information about chronic
health effects of mercury exposure in gold mining (see
bottom right corner in Fig. 1). Reports from other
international institutions about mercury were excluded
because of other main foci (e.g., food (EFSA), environ-
ment (UNEP), industrial development (UNIDO)). Sec-
ond, a PubMed search was done to find reviews on
the predefined exposure and health outcome of inter-
est. The keywords, review, elemental/metallic, mercury,
exposure/health/intoxication/poisoning/toxicity, chronic,
and vapor were combined to find sufficient search terms.
Criteria for exclusion, like a focus on treatments or experi-
mental studies, were applied which are listed in Fig. 1.
The PubMed search was restricted to articles published
between 1999 and March 2013 because a comprehensive
report reviewing relevant literature [39] was published in
1999. All references included were screened to identify
relevant chapters about symptoms, caused by the prede-
fined exposure in humans, and their severity and probabil-
ity of occurrence.
When screening the literature, difficulties were faced
in identifying symptoms specifically attributable to the
exposure of interest. In some cases, information about
the form of mercury and the duration or pathway of
exposure was missing in the references used. Only those
symptoms were included where information on the
exposure was available.
Combining information from different sources
In total, the disease profiles are based on ten sources
belonging to three types of sources: The transcript of
the interview, one presentation from the expert meeting,
and eight literature references [36–43] (Fig. 1). The infor-
mation about common symptoms, probability of symptom
occurrence, and symptom severity was extracted from the
interview transcript and presentation slides and comple-
mented by the information identified in the literature
(Additional file 1; File S5).
The list of symptoms was structured by applying cat-
egories of the system or part of the body affected as used
in the considered literature while some adaptions were
necessary (Additional file 1; File S5; column A). The ad-
vanced search-function of the online ICD-10 list [44]
was used to ensure that symptoms were assigned to the
correct categories and to identify synonyms describing
the same symptom.
The condensed disease profiles were prepared on the
basis of the comprehensive list of symptoms (Additional
file 1; File S5). Symptoms were included in the disease-
specific description of the profiles if they were confirmed
by more than two sources, and – if available – described
as a common symptom, or at least not as uncommon.
Consequently, the profiles do not contain a complete list
of symptoms but the common and frequent mentioned.
Where several terms were used for the same symptom
(Additional file 1; File S5; column B), one term was
chosen for further usage (Additional file 1; File S5; col-
umn C). Information about symptom severity allowed
the distinction in disease stages. Where no information
about increasing or decreasing severity was available, the
common symptoms were attributed to all stages (Add-
itional file 1; File S5; columns D, E, and F).
The generic disease description is completely based on
the interview because it was not possible to extract such
specific information from the literature. The EQ-5D + C
valuation was checked again by the experts of the initial
discussion group after seeing the finalized disease-specific
description to ensure suitability to the condensed list of
symptoms. The final disease profiles were also checked by
the experts.
Results
The interview participants agreed to label the disease
chronic metallic mercury vapor intoxication (CMMVI)
to describe the health outcome of interest within the
project [a]. The experts confirmed mild, moderate, and
severe stages of CMMVI. However, for the project pur-
pose, a dichotomous differentiation of stages (moderate
and severe) seemed feasible. This became clear during
the assessment of the HRQoL and during literature
search. A distinction of CMMVI in three stages was less
expedient while a sharp distinction was achieved when
focusing on two disease stages [b]. The disease-specific
description including the exposure [c] and health situation
[d] and the generic description indicating the HRQoL of
CMMVI [e] are described in detail below. The disease
profiles of moderate and severe cases of CMMVI includ-
ing the components [a] to [e] are presented in Table 1.
Disease-specific description
The exposure of the case of interest is described as
adults chronically exposed to metallic mercury vapors,
corresponding to the main exposure of ASGM workers
and mercury miners [c]. Hence, individuals similarly
exposed to mercury, e.g., due to accidents [45] or by
working in other industries with comparable exposure
settings like in industries which use or emit mercury,
such as power and heating plants (due to fossil fuel
combustion), metal and cement production, waste in-
cineration, or mercury mining [3], also fall under the
general description of the exposure setting. Conse-
quently, the disease profiles developed can be used if
the exposure scenario (form of mercury, exposure path-
way, etc.) is the same as in ASGM. All other types of
mercury exposure (e.g., other forms of mercury, exposure
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pathways, or durations of exposure or dosages), other con-
comitant exposures (e.g., other chemicals, other hazards
such as noise or accidents), or comorbidities (e.g., acute
intoxications, cancer, silicosis, cardiovascular or infectious
diseases) were not considered for the current definition of
CMMVI. Examples for other mercury-related health out-
comes are Minamata disease, acrodynia/pink disease, mild
mental retardation, kidney damage, or acute intoxications,
which might have similar but also different clinical symp-
toms [39] than CMMVI. Due to the focus on adult gold
miners, children were excluded from the case description.
The complete list of symptoms as identified in the ten
sources used is included in Additional file 1; File S5.
More than 250 synonymous terms of symptoms (includ-
ing nearly 60 health signs like abnormal laboratory
findings such as proteinuria) were summarized in 85
distinguishable symptoms and, with reference to ICD-
10 and the categories used in the literature, assigned to
dermal, endocrine, digestive, general, hematological, im-
munological and lymphoreticular, metabolic, neurological,
renal, and respiratory effects. The neurological effects
were further subsumed in categories depending on
whether they affected the musculoskeletal system, led to
behavioral, cognitive, emotional, or mental effects, or af-
fecting other systems (auricular, ocular, speech).
Twenty-nine of the 85 symptoms were mentioned in
more than two of the ten sources and included in the
moderate and/or severe disease profiles ([d], Fig. 2). Con-
sidering the information about symptom severity and
probability of occurrence, a list of 23 and 26 symptoms [d]
were included in the disease profiles of moderate and
severe cases, respectively (Table 1).
The symptoms included in the disease profiles are
categorized as neurological effects regarding the mus-
culoskeletal system (e.g., tremor) and in terms of be-
havioral, cognitive, emotional, and mental effects (e.g.,
fatigue, loss of confidence). For moderate CMMVI cases,
the neurological symptoms reflex abnormalities, periph-
eral nerve abnormalities, and sensory disturbances are
listed separately. For severe cases, the additional term
polyneuropathy, meaning the presence of symptoms of the
peripheral nerve system, was included. The neurological
symptom difficulty seeing (effects on the ocular system)
was included into the profile of the severe but not the
moderate case. Furthermore, renal (e.g., proteinuria),
digestive (e.g., loss of appetite), and immunological and
lymphoreticular effects (immunological changes) were
included in both profiles with different symptoms and/or
symptom severities. By implication, dermal, endocrine,
hematological, metabolic, respiratory effects, and neuro-
logical effects of the auricular system or speech, while
reported symptoms of CMMVI, are identified as uncom-
mon and/or rarely described and so were not included in
the disease profiles.
For some symptoms, there are indications that in the
most severe cases, new symptoms may occur either
together with or instead of a symptom of a moderate
case. Following the interview, the symptom dry mouth
(effect of the digestive system) might replace salivation
in very severe cases (Additional file 1;File S5 row 9).
Table 1 Disease profiles of the moderate and severe cases of chronic metallic mercury vapor intoxication (CMMVI)
Disease label [a] Chronic Metallic Mercury Vapor Intoxication (CMMVI)
Disease stage [b] Moderate case Severe case
Disease-specific description
(including exposure [c] and
health situation [d])
Adults with high mercury body burden caused by chronic
inhalation of metallic mercury vapor who show several of
the following symptoms:
Adults with a very high mercury body burden caused by
chronic inhalation of metallic mercury vapor who show
several of the following symptoms:
• Slight tremor of fingers, hands, and limbs;
coordination problems; dysfunction of movement control;
weakness
• Reflexes abnormalities; peripheral nerve abnormalities;
sensory disturbances
• Sleep disorders; irritability; nervousness; fatigue; memory
impairment; difficulty in concentration; shyness; depressive
mood; loss of confidence; lack of self-control
• Renal effects like enzymuria, proteinuria, and glomerular
dysfunction, increased urinary excretion of
N-acetyl-β-glucosaminidase (NAG)
• Loss of appetite; salivation
• Immunological changes
• Pronounced tremor in several parts of the body; severe
coordination problems; dysfunction of movement control;
weakness
• Polyneuropathy
• Insomnia; hyperirritability; nervousness; fatigue; loss of
memory; difficulty in concentration; extreme shyness;
depression; loss of confidence; lack of self-control; social
avoidance
• Abnormal renal function with enzymuria, high
proteinuria, glomerular dysfunction, and rising urinary
excretion of N-acetyl-β-glucosaminidase (NAG)
• Anorexia; excessive salivation; gingivitis; stomatitis
• Immunological changes
• Difficulty seeing
Generic description
(EQ-5D + C [e])
• No problems in walking (1)
• Some problems with self-care (2)
• No problems with performing usual activities (1)
• Moderate pain or discomfort (2)
• Moderately anxious or depressed (2)
• Some problems in cognitive functions (2)
• Some problems in walking about (2)
• Not able to wash or dress themselves (3)
• Not able to perform usual activities (3)
• Severe pain or discomfort (3)
• Extremely anxious or depressed (3)
• Severe problems in cognitive functions (3)
[a] to [e]: A description of the components [a] to [e] is given in the chapter “Methods”. (1), (2), (3): EQ-5D + C code; (1) no problems, (2) problems, (3) severe prob-
lems. EQ-5D + C: the five EuroQol dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) plus cognition (EQ-5D + C) questionnaire
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Moreover, muscular spasms (neurological effect of the
musculoskeletal system) may occur simultaneously with
extremely severe tremor, which is described in one litera-
ture reference [37] (Additional file 1; File S5; row 49).
However, these symptoms were not included in the pro-
files, because they are mentioned in just one or two
sources.
In most cases, symptoms rather than specific signs
were included in the profiles (e.g., tremor was in-
cluded while a change in handwriting was not expli-
citly mentioned). Exceptions are made regarding renal
effects (Additional file 1; rows 75–89). The laboratory
signs frequently mentioned, enzymuria, proteinuria,
and increased urinary excretion of N-acetyl-β-glucosa-
minidase (NAG), were classified as renal effects (mod-
erate case) and as abnormal renal function (severe
case) and included in the profiles partly by including
information about severity (e.g., proteinuria in the
moderate case and high proteinuria in the severe
case). The nephrotic syndrome is the only frequently
mentioned symptom which was not included in the
disease profile,s because it is described as uncommon
[37] or rare [43] (Additional file 1; File S5; row 77).
Peripheral nerve abnormalities are mentioned in seven
of ten sources (Additional file 1; File S5; row 33). One
source describes it as prominent [38] but another as un-
common [42] while the remaining five sources give no
information about the frequency of occurrence. This
contradiction was resolved by treating peripheral nerve
abnormalities as a common symptom because it is men-
tioned so often.
No reference reported an increase or decrease of
the common CMMVI symptoms loss of confidence, diffi-
culty in concentration, dysfunction of movement control,
enzymuria, fatigue, glomerular dysfunction, immunological
changes, lack of self-control, nervousness, and weakness.
Consequently, they seemed to be independent from the
severity level, which is why they were included in both
disease profiles (moderate and severe case) without vari-
ation. All other symptoms included in the disease profiles
were either described with increasing intensity (e.g., irrit-
ability and slight tremor in the moderate, and hyperirrita-
bility and pronounced tremor in severe cases) or with
initial occurrence in severe cases (e.g., difficulty seeing).
From the 29 symptoms included in the moderate and/
or severe disease profiles, 14 are mentioned in the inter-
view, the presentation, and the literature (Fig. 2). Be-
cause symptoms were included in the disease profiles if
they appeared in more than two of the ten sources,
symptoms mentioned only in the interview and/or the
presentation but not in the literature were excluded.
This was the case for changing hormone levels (endo-
crine effect), changing taste, coloration of the oral cavity,
dry mouth, loss of teeth (all effects of the digestive sys-
tem), higher level of glutathione and changing catalase
(hematological effects), oxidative stress (metabolic ef-
fect), sadness (neurological effects in terms of behavioral,
cognitive, emotional, mental effects), and subclinical
Fig. 2 Visualization of the number of sources describing each symptom included in the disease profiles
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urea level. Many symptoms also were excluded because
they were mentioned in only one or two references
(Fig. 3).
Erethism, frequently described as resulting from chronic
exposure to metallic mercury vapors [36, 37, 39, 41–43]
(Additional file 1; File S5; row 70), was not included
in the profiles because it overlaps with other symp-
toms and its description changed over time [43]. In
the profiles, the symptoms subsumed under erethism
(e.g., irritability, shyness, loss of memory, etc.) were
included.
Generic description
The generic descriptions of moderate and severe cases,
as determined by the expert interview following the
EQ-5D + C-3L evaluation, were compared to a healthy
person (Table 2) and included in the health profiles
(Table 1). The expert elicitation yielded the assessment
Presentation
Interview
• changing catalase
• dry mouth
• Increased glutathione
levels
• oxidative stress 
• subclinical urea levels
• changing
hormone level
• changing taste
• coloration of the 
oral cavity
• loss of teeth 
• sadness
Literature
Symptoms mentioned in one review: • anemia • bone marrow irritation
• changes in the specific gravity of urine • cough • damage to the lining of the lungs
• deafness • dizziness • dysdiadochokinesis • dyspnea • eosinophilia • fever
• increase in anti-DNA antibodies • increase in total IgE in serum • increased plasma
concentrations of beta-galactosidase • increased plasma concentrations of proteins
• increased urinary excretion of tubular antigens • lymphocytosis • malaise • muscle
atrophy • muscular spasms • polycythaemia • sweating • unspecified oropharyngeal
symptoms • urinary dysfunction
Symptoms mentioned in two reviews: • anger • anxiety • confusion • decreased
excretion of molecules • decreased urinary excretion of some glycosaminoglycans
• decreased urinary pH • decreasing intelligence • delirium • diarrhea • evoked
potentials • muscle cramps • muscle fasciculations • muscle pain • myoclonus
• paresthesia • tremulous speech • weight loss
• dermographism
• trembling
• headache Symptoms included in 
profiles, see Fig. 1
• /
No symptom is
mentioned exclusively
in the presentation
Fig. 3 Symptoms not included in the disease profiles of CMMVI which were mentioned in only one or two sources
Table 2 Visualization of the restrictions in the health-related quality of life (HRQoL) when comparing moderate and severe cases
with healthy person
Criteria Healthy persons Moderate CMMVI cases Severe CMMVI cases
Mobility 1 1 2
Self-care 1 2 3
Usual activities 1 1 3
Pain/discomfort 1 2 3
Anxiety/depression 11 2 3
Cognition 2 3
EQ-5D + C-3L Code 111111 121222 233333
1: No restrictions in the health-related quality of life (HRQOL)
2: Moderate restrictions in the HRQoL
3: Severe restrictions in the HRQoL
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that the quality of life is effected regarding mobility and
usual activities in severe but not in moderate cases. How-
ever, the criteria self-care, pain, anxiety, and cognition are
always affected by CMMVI. However, their expression
(problems or severe problems) depends on the severity of
the disease.
In moderate cases, some problems with self-care and
cognitive functions were assumed to be accompanied by
moderate pain or discomfort in a moderately anxious or
depressed individual. Problems in walking about or
performing usual activities were not assumed. On the
other hand, restrictions in all six categories (problems
or even severe problems) are expected in severe cases.
Individuals with a severe CMMVI may have some prob-
lems with walking about, but severe problems with cogni-
tive functions, severe pain or discomfort, be extremely
anxious or depressed, not able to wash or dress themselves
or to perform usual activities. Following the EQ-5D +C
coding system, the moderate and severe cases were valued
as 121222 and 233333, respectively.
Discussion
Disease profiles of moderate and severe CMMVI were
developed according to the specific exposure situation of
ASGM, including a list of common symptoms in the
disease-specific description and EQ-5D +C-3L codes in
the generic description. Information from the literature (8
selected reviews) was combined with expert knowledge
(interview transcript and presentation) to address the
research questions. This is the first time that a mercury-
related health outcome was assessed with EQ-5D + C and,
generally, regarding its HRQoL.
A total of 85 distinct symptoms were extracted from
the literature and the expert interview. This broad range
of health effects was narrowed down to the essential in-
formation to distinguish two severity levels of CMMVI,
including only frequently mentioned symptoms in the
disease specific descriptions. All symptoms included in
the description of moderate CMMVI cases are repre-
sented in the description of the severe cases, but more
than half of the symptoms worsen from moderate to
severe cases. A few symptoms were assumed to occur
only in severe cases. The descriptions of symptoms ex-
tracted from the ten sources used are very unspecific in
some cases (e.g., immunological changes; difficulty
seeing).
The aim of the project was to develop disease profiles
for the derivation of DWs to improve the data basis for
estimating the BoD due to CMMVI as result of the mer-
cury use in ASGM. Several methodological choices are
possible for DW derivation; however, in addition to the
description of health states, the valuation method and
the composition of the panel are key components.
Pairwise comparisons, time or person trade-off (TTO,
PTO) and visual analogue scale (VAS) are established
methods for assessing the severity of health states. A
panel consisting of mostly experts or other subgroups
such as samples of the general population or patients is
asked to assess the severity of different health states.
The health states were presented as disease-specific and/
or generic descriptions [29]. The assessments of the
panel are then converted to the DW, which ranges be-
tween zero and one [22, 29]. The disease profiles of
CMMVI are designed for use in such DW derivations.
The profiles are developed in a means comparable to
profiles of other diseases already published. Haagsma
and colleagues [29] identified six DW studies using both
disease-specific and the generic EQ-5D description for
disease profiles, also [20, 21, 25–28]. However, the deci-
sion which available set of disease profiles are used for
comparisons with the profile of CMMVI might be
followed by further adaptions of the disease-specific part.
The reasons are individual differences of the sets of pro-
files like the length of descriptions or writing styles.
Further, distinctions in more than two disease stages
seemed to be possible because some single symptoms
may worsen before others (Additional file 1; File S5; col-
umns D and E). For example, neurological and renal ef-
fects are generally seen earlier than effects in other
organs [38]. Hence, slight renal involvement might ap-
pear before neurological effects, while chronologically
the central nervous system was assumed to be affected
before the kidneys [37, 40]. Furthermore, tremors occur
a little after minor psychological disturbances (e.g., shy-
ness) [36] while psychological, renal, and neurological ef-
fects can be assumed before other organs are involved.
Although further distinctions seemed possible, very de-
tailed and individual disease profiles are not useful from a
public health point of view, when aiming on improving
the data basis for BoD analyses. However, it must be kept
in mind that health and disease are distributed differently
amongst individuals and are influenced by factors like the
environment, lifestyle, and genetics (exposome) [46].
There is individual variation in mercury intoxication [36,
40, 43] while several symptoms are unspecific and do not
always appear [43] and even subclinical intoxications are
possible [47].
The unspecificity of the symptoms became clear when
using the ICD-10 list to arrange the symptoms in cat-
egories. Most symptoms are listed in the ICD-10 chapter
R00-R99, Symptoms, signs and abnormal clinical and
laboratory findings, not elsewhere classified. Due to the
generality of the symptoms, their occurrence is not
limited to chronic exposure to elemental mercury vapors
but to a number of other diseases and causes.
The disease profiles are developed for a strictly defined
case description. Specific topics were excluded, although
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they are relevant to the use of mercury in gold mining
and should be subject of future research. The profiles
focus on adults while children were excluded. The spe-
cific health outcomes of children exposed to mercury in
ASGM should definitely be included in future research
because child labor is very common in gold mining [7].
Separate disease profiles should be developed with a focus
on children because it is likely that they are affected differ-
ently than adults. For example, children might develop a
skin reaction called acrodynia what is not common in
adults.
A further subject of future research should be comor-
bidities. Although comorbidities are very common in the
occupational settings described [48–50], they should not
be addressed until single risk hazards have been identi-
fied. For example, the Global Burden of Disease 2010
Study considers co-morbidities when deriving DWs and
not earlier in the disease descriptions [22].
The disease profiles should be incorporated into diag-
nostic criteria for epidemiological data surveys. Some
surveys about mercury exposure of gold miners are
available and their data should be examined to identify
cases of CMMVI. Some existing surveys use a diagnostic
tool developed by Drasch et al. (2001) [51] to identify
chronic mercury intoxications [51–54]. The tool com-
bines information on the concentration of mercury in
human biomonitors and health effects, while no distinc-
tion was made regarding the form of mercury and symp-
toms. This diagnostic tool should be compared with the
disease profiles in this paper and can be used as starting
point to define criteria for diagnosing CMMVI.
The project was based on published information and
expert elicitation, while consulting the affected individ-
uals themselves was not an option. Interviewing experts
was deemed as acceptable approximation and valuable
supplementation to information from the literature, be-
cause experts revealed relevant and unpublished infor-
mation. The expert elicitation was particularly valuable
regarding the EQ-5D + C because the quality of life of
patients with mercury intoxication had not been assessed
previously. Open discussions of the HRQoL were pre-
ferred to individual expert assessments on order to base
the final decision on the joint knowledge of the group.
Applying a standardized instrument like the Delphi
method was rejected due to the limited timeframe. How-
ever, the open discussion could have promoted consen-
suses and could have prevented the expression of ideas or
possible disagreements which probably would have oc-
curred, if the opinions were written and anonymous. The
experts pointed out ten symptoms not mentioned in the
reviews (Fig. 3). Particularly interesting is the information
from the interview, that salivation might be substituted by
a contrary symptom (dry mouth) in very severe cases. Due
to the predefined inclusion criteria those symptoms were
not included in the disease profile, but indicated the need
for further research to study the association between
CMMVI and the symptoms identified by the experts.
Furthermore, in some cases the experts consulted yielded
information on the probability of symptom occurrence or
severity. Thus, social avoidance was included in the pro-
files as a symptom of severe cases (Table 1).
Using proxies to determine the HRQoL has been done
before, e.g., relatives, friends, or professional caregivers
were questioned if patients themselves were unable to
answer the questionnaire due to illness or insufficient
cognitive abilities (e.g., critically ill patients [55], patients
with dementia [56], or young children [57, 58]). While
the agreement between patients and proxies was rela-
tively good in some studies (e.g., [55]), there is evidence
that proxies tend to report a lower quality of life than
the patients themselves [59, 60]. In future studies, the
project results should be confirmed by involving a suffi-
cient number of affected people to determine the patients’
reported outcome (PRO) [61].
Having the HRQoL determined by relatively few experts
is a limitation of the project, however, it is a common ap-
proach. A comprehensive review including 154 HRQoL
studies identified that in more than the half of the studies
the assessment was done by experts or even by the au-
thors themselves. The sample size ranged from one to
2579 respondents, while the maximum panel size of ex-
perts was 140 [62]. HRQoL assessment by comparatively
few experts was also observed in a specific review of liver
diseases involving 30 studies. With one exception (n <
100), the expert panels consisted of four to seven individ-
uals [63]. The small panels may be a result of the limited
number of experts on specific topics. An absolute guide-
line about the appropriate number of experts is not avail-
able, while a symposium on expert judgment policy in risk
and environmental studies recommended of six to 12 ex-
perts [31, 64]. In the current study, it was possible to in-
clude five experts, which is close to the recommendation.
The EQ-5D + C assessment confirmed the differenti-
ation of CMMVI into two stages due to the varying
HRQoL. The resulting EQ-5D +C codes, 121222 for mod-
erate and 233333 for severe cases, are comparable to
assessments of other diseases. In the Dutch Disability
Weight study, 175 disease stages were evaluated using the
EQ-5D + C protocol [24]. No disease stage of the Dutch
study has the same EQ-5D +C code as a moderate
CMMVI case. Nevertheless, the criteria self-care, pain,
anxiety, and cognition of a moderate CMMVI case are
evaluated similar to the intermediate stage of Parkinson’s
disease in the Dutch study. Indeed, the other two criteria,
mobility and usual daily activities, were considered more
severe in Parkinson’s disease (code 223222) than in a
moderate CMMVI case (121222). A severe CMMVI case
is assessed using the same code as schizophrenia at the
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stage several psychotic episodes, severe and increasing per-
manent impairments in the Netherlands [24].
Interesting is a comparison with the EQ-5D + C evalu-
ation of alcoholism. In a previous attempt to estimate the
BoD due to chronic mercury intoxication, the missing
DW was replaced by a provisional DW of a comparable
disease. The DW for alcoholism was chosen because alco-
holism, like chronic mercury intoxication, is triggered by a
substance, it shows comparable health symptoms, and it is
a chronic condition [9]. In the Dutch DW study, the
EQ-5D + C code for manifest alcoholism was assessed
with 113221 [24]. The criteria mobility, pain/discomfort,
and anxiety/depression are given values equal to a moder-
ate case of CMMVI. However, the criteria, self-care and
cognition, seemed to be greater problems in CMMVI
while usual activities are highly restricted in patients with
alcoholism and not in patients with moderate CMMVI.
The EQ-5D is brief and simple. The questionnaire is
among the leading generic measures of HRQoL [65].
The sixth dimension, cognition, was added to the initial
five dimensions of the EuroQol questionnaire – as was
done in other studies (e.g. [24]) – to describe the compo-
nents of CMMVI affecting cognitive aspects. Both moder-
ate and severe cases show cognitive problems, confirming
the choice of including the additional dimension.
As a result of the exclusion criteria defined, a small
number of selected review articles were included, which
might limit the project results. Even though, a full review
of original articles might yield an even broader view on
the symptoms of CMMVI, this would go far beyond the
scope of the current assessments and would not be
helpful to condense the available evidence. The profiles
include only common symptoms and no case exceptions.
Conclusions
Chronic exposure to metallic mercury vapor causes a
range of symptoms. Based on knowledge obtained from
experts and selected literature, disease profiles were set
up for moderate and severe cases of CMMVI, including
common symptoms and assessments of the HRQoL.
Further steps, such as deriving DWs and conducting
epidemiological data surveys, are needed to improve
ascertainment and reporting of CMMVI, which is a
requirement for developing and introducing prevention
strategies to protect the workers’ health.
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